Use of β-blockers during immunotherapy for Hymenoptera venom allergy

Müller, Ulrich; Haeberli, Gabrielle

doi:10.1016/j.jaci.2004.11.012

Cited by 133 publications

(81 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elderly patients with HVA and cardiovascular disease treated with beta-blockers are considered to be particularly at high risk of severe SSR in the case of an insect sting. 23 Based on the risk/benefit profile, there is no contraindication for VIT in patients treated with beta-blockers. analyses, results are often confounded by patient's older age which has been shown to be a strong risk factor for more severe SSR.…”

Section: Beta-blockersmentioning

confidence: 99%

“…45 Although still a debated issue, ACE inhibitors and beta-blockers are not considered to be independent risk factors for adverse events. [23][24][25] Importantly, severe initial sting reactions, 24,25,84 positive skin tests at low test concentrations and high specific IgE levels 25,84,85 are not regarded as risk factors for adverse events ( …”

Section: Effectiveness During/after Maintenance Vitmentioning

confidence: 99%

See 1 more Smart Citation

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

Sturm

Varga

Roberts

et al. 2017

Allergy

398

528

View full text Add to dashboard Cite

Hymenoptera venom allergy is a potentially life‐threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic‐allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life‐threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1‐antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence‐based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta‐analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom‐allergic children and adults to prevent further moderate‐to‐severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence‐based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.

show abstract

Section: Beta-blockersmentioning

confidence: 99%

Section: Effectiveness During/after Maintenance Vitmentioning

confidence: 99%

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

Sturm

Varga

Roberts

et al. 2017

Allergy

398

528

View full text Add to dashboard Cite

show abstract

“…3 In our case, it appears that the patient experienced an allergic reaction to a new cellulose-containing beta-blocker preparation. He was slow to treat and resuscitate, plausibly because of a longstanding history of beta-blocker use and gastroenteritis caused by norovirus infection.…”

Section: Discussionmentioning

confidence: 62%

A new urticarial rash, diarrhoea and refractory hypotension in a man with a history of migraines

Lamb

Lowe

2016

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…No beta blockers or angiotensin receptor inhibotors were used due to reported potential risk of severe anaphylaxis [10][11][12][13][14]. These agents may cause mast cell degranulation.…”

Section: Patient Managementmentioning

confidence: 99%

Case report on aortic valve replacement in adult woman with systemic mastocytosis (RCD code: VIII)

Różewicz-Juraszek

Hryniewiecki²,

Faber³

et al. 2017

Journal of Rare Cardiovascular Diseases

View full text Add to dashboard Cite

We present a case of a 50 year-old woman who was referred to our department with severe symptomatic aortic stenosis and systemic mastocytosis. Conventional mechanical aortic valve replacement was performed successfully with the use of perioperative protocol based on dexamethasone, cetirizine and ranitidine. The only postoperative event was an onset of atrial fibrillation which was treated with amiodarone infusion. 8 days after surgery the patient was discharged home. JRCD 2017; 3 (2): 54-55

show abstract

Use of β-blockers during immunotherapy for Hymenoptera venom allergy

Cited by 133 publications

References 31 publications

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy

A new urticarial rash, diarrhoea and refractory hypotension in a man with a history of migraines

Case report on aortic valve replacement in adult woman with systemic mastocytosis (RCD code: VIII)

Contact Info

Product

Resources

About